Standout Papers

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer 2023 2026 2024154
  1. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer (2023)
    Gerald W. Prager, Julien Taı̈eb et al. New England Journal of Medicine

Immediate Impact

37 standout
Sub-graph 1 of 13

Citing Papers

Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
Digestive cancers: mechanisms, therapeutics and management
2025 Standout
1 intermediate paper

Works of Catherine Leger being referenced

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
2023 Standout
Trifluridine/Tipiracil Plus Bevacizumab for Third-Line Management of Metastatic Colorectal Cancer: SUNLIGHT Study Design
2021

Author Peers

Author Last Decade Papers Cites
Catherine Leger 196 88 70 10 232
Pierre-Guillaume Poureau 197 84 66 12 237
Merete Krogh 189 68 41 17 222
Loïck Vidot 189 69 73 11 228
Nisha L. Jacobs 195 75 65 10 269
Erica N. Heying 217 83 89 10 275
Patrick Texereau 219 91 49 15 274
Rosa Rita Silva 186 86 45 18 250
Loïc Bergougnoux 216 65 33 6 255
Dong Ma 184 75 54 11 268
Philippe Ronga 173 77 37 13 243

All Works

Loading papers...

Rankless by CCL
2026